The research for development of polyvalent lived vaccine based on current varicella vaccine

DOI Web Site 29 References
  • Koshizuka Tetsuo
    Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation
  • Mori Yasuko
    Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation Division of Clinical Virology, Kobe University Graduate School of Medicine

Bibliographic Information

Other Title
  • 組換えウイルスキャリア‐遺伝子治療・ワクチン応用への新展開‐組換え水痘ウイルスを用いた多価生ワクチン開発の研究
  • 組換え水痘ウイルスを用いた多価生ワクチン開発の研究
  • クミカエ スイトウ ウイルス オ モチイタ タカ ナマ ワクチン カイハツ ノ ケンキュウ

Search this article

Abstract

Varicella-zoster virus (VZV) infection is a causative agent of varicella and zoster. Varicella vaccine has been developed to reduce the morbidity of varicella. The Oka vaccine is the only attenuated live varicella vaccine permitted for use by WHO.<BR>Recently we have generated a recombinant virus expressing mumps virus (MuV) HN protein based on the varicella vaccine. The recombinant virus could induce neutralizing antibodies against both VZV and MuV in guinea pig, thus indicating that the virus may be a candidate for polyvalent live vaccine against MuV and VZV infection.<BR>Here we have summarized about the Oka vaccine, the recombinant virus and the application for a polyvalent live vaccine of the recombinant virus.

Journal

  • Drug Delivery System

    Drug Delivery System 24 (6), 592-598, 2009

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(29)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top